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GABAA receptors (GABAARs) composed of  subunits are allosterically modulated by the benzodiazepines (BDZs). Agonists at
the BDZ binding site potentiate submaximal GABA responses by increasing the apparent affinity of GABAARs for GABA. Although
BDZs were initially thought to affect the binding of GABA agonists, recent studies suggest an effect on receptor gating; however, the
involvement of preactivation steps in the modulation by BDZs has not been considered. Consequently, we examined whether BDZ
agonists could exert their modulatory effect by displacing the equilibrium between resting and preactivated states of recombinant
122 GABAARs expressed in Xenopus oocytes. For GABA and the partial agonists 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-
3-ol and piperidine-4-sulfonic acid, we examined BDZmodulation using a simple three-step model incorporating agonist binding,
receptor preactivation, and channel opening. The model accounted for diazepam modulation simply by increasing the preactiva-
tion constant by approximately fourfold. To assess whether BDZs preferentially affected a specific GABA binding site, pentameric
concatamers were used. This demonstrated that single GABA-binding site mutant receptors were equally sensitive to modulation
by BDZs compared with wild-type counterparts. Overall, our results suggest that BDZs affect the preactivation step to cause a
global conformational rearrangement of GABAARs, thereby modulating receptor function.
Introduction
GABAA receptor (GABAARs) are members of the Cys-loop
ligand-gated ion channel family, which also comprises nicotinic
acetylcholine, glycine, and 5-HT3 receptors. They form pentam-
eric heteromers whereby the extracellular domains of each sub-
unit contribute toward a pseudo-symmetrical ring providing two
binding sites for GABA located at the / interfaces (Ernst et al.,
2003; Smart and Paoletti, 2011). GABAARs display considerable
heterogeneity as a result of numerous subunit families (Korpi et
al., 2002), but generally, the most prevalent subtypes found at
inhibitory synapses throughout the brain are assembled from
 subunits (Whiting et al., 1995).
These  receptors are functionally modulated by the ben-
zodiazepines (BDZs) (Korpi et al., 2002), which bind to the /
extracellular interface (Sigel, 2002). At nonsaturatingGABA con-
centrations, BDZagonists potentiateGABA responses by increas-
ing the apparent affinity of the receptor for GABA. Because this is
unaccompanied by increased efficacy of channel gating, it had
long been thought that BDZ agonists simply increased the bind-
ing affinity of GABA agonists (Study and Barker, 1981; Twyman
et al., 1989; Rogers et al., 1994). However, this traditional view
has been challenged because BDZ agonists not only potentiate
responses elicited by saturating concentrations of partial agonists
at the GABA binding site (Maksay et al., 2000; Downing et al.,
2005; Ru¨sch and Forman, 2005) but also directly gate GABAARs
that are spontaneously active (Bianchi and Macdonald, 2001;
Campo-Soria et al., 2006). These results are incompatible with
BDZs solely affecting GABA binding affinity, suggesting that an
alternative allosteric mechanism needs to be considered.
For some members of the Cys-loop receptor family, agonist
efficacy has been shown to depend on the equilibrium between a
ligand-bound resting state and a ligand-bound preactivated
(flipped) state that is still inactive, whereas the final step involving
channel opening remains almost equally efficient for both full
and partial agonists (Lape et al., 2008; Mukhtasimova et al.,
2009). Our study provides the first evidence that BDZs canmod-
ulate GABAARs by simply shifting the equilibrium between the
ligand-bound resting and preactivated states before channel
opening, rather than by affecting affinity or efficacy.
Materials andMethods
Molecular biology.GABAARsubunits (1,2,2S, and2L)were subcloned
into pRK5. For constructing the concatamer, five subunits were assembled
into a single open reading frame, separated by polyglutamine linkers in the
order 2–1–2–1–2S. The concatamer was cloned in pRK5 between
ClaI and HindIII restriction sites after removing the endogenous HindIII
sites from the 2 subunits. The five individual subunits were recloned after
PCR to encode unique flanking restriction sites. Inverse PCRwas then used
to add 20 primer-encoded glutamines to the C-terminal end of the 2 sub-
units and 15 to the end of the1 subunits. The initial2 subunit was cloned
into a low copy number vector pRK5, and the remaining subunits were
sequentially added. The initial2 subunit contained the signal peptide and a
myc epitope tag, inserted between amino acids 4 and 5 of the mature 2
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subunit protein. All the other subunits were composed only of their mature
proteins. To enhance translation, a 37 bp 5 UTR from Xenopus oocyte
globin was added to the first subunit (2), and the Kozak sequence was
optimized. Between theClaI andHindIII restriction sites, the final construct
order is ClaI–Kozak–2myc–20Q–AgeI–1–15Q–SalI–2–20Q–NheI–
1–15Q–XhoI–2S–Stop–HindIII. Concatamers containing selected point
mutations in either of the two 2 subunits (SU1–Y157S and SU3–Y157S)
were prepared by mutating the corresponding single subunits, which were
then recloned into the concatamer.
Expressing GABAARs in Xenopus laevis oocytes. Ovaries were re-
moved from female African clawed frogs (Xenopus laevis) using pro-
cedures approved by the Animals (Scientific Procedures) Act 1986.
Free oocytes were obtained by incubating segments of ovary in colla-
genase type 1 (Worthington) dissolved in a Ca 2-free OR2 solution,
which contained the following (in mM): 85 NaCl, 5 HEPES, and 1
MgCl2, pH adjusted to 7.6 with KOH. After 2–4 h exposure to colla-
genase I, defolliculated oocytes were washed several times with OR2
and thereafter maintained in a Barth’s solution containing the follow-
ing (in mM): 88 NaCl, 1 KCl, 0.33 Ca(NO3)2, 0.41 CaCl2, 0.82 MgSO4,
2.4 NaHCO3, and 10 HEPES, pH adjusted to 7.6 with NaOH. Single
oocytes were injected with 27.6 nl of GABAAR subunit cDNAs (nu-
clear injection), in a ratio for 1/2/2 of 1:1:10 using a total cDNA
concentration of 20 ng/l for expressing GABAAR heteromers or 30
ng/l for the concatamers. Oocytes were incubated at 17°C in Barth’s
solution devoid of serum or antibiotics.
Two-electrode voltage-clamp recording.Oocytes expressing regular het-
eromeric receptors were used 1 d after injection, whereas the pentameric
concatamers typically showed robust expression after 2–3 d (maximal
currents ranged from 500 nA to 2 A). They were superfused with a
solution containing the following (in mM): 100 NaCl, 2 KCl, 2 CaCl2, 1
MgCl2, and 5 HEPES, pH adjusted to 7.4 with NaOH. Currents were
recorded using an Axoclamp 2B amplifier, a Digidata 1322A interface,
and pClamp 8 (Molecular Devices). Currents were digitized at 500 Hz
and filtered at 50 Hz (10 Hz used for display purposes). Oocytes were
voltage clamped at 60 mV, and experiments were conducted at room
temperature.
Data analysis. Concentration response data were fitted with the Hill
equation (below) or one based on a three-step linear reaction scheme (see
Results; Origin version 6; OriginLab):
I/Imax  1/1  EC50/A
nH).
For the Hill equation, I and Imax represent the current induced by
various agonist concentrations and the maximal agonist-activated
current, respectively, [A] is the agonist concentration, EC50 is the
concentration producing a half-maximal response, and nH is the
Hill coefficient. GABA data points were normalized to provide a max-
imal current of 1 in control and in the presence of diazepam. Al-
though this is a constraint, it accords with the consensus view from
the literature, and, after normalization, the diazepam-induced poten-
tiation of responses to 1 mM GABA is predicted to be 13% for
122S receptors, which falls within the experimentally measured
range (7  11% potentiation; n 	 6; Fig. 1). Under control condi-
tions, 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol (THIP) data
points were normalized according to the ratio of currents for 1 mM
GABA and 10 mM THIP, whereas the THIP data points in diazepam
were normalized according to the potentiation of the responses to 10
mM THIP by diazepam. In control and in the presence of diazepam,
piperidine-4-sulfonic acid (P4S) data points were normalized accord-
ing to the current ratio between 1 mM GABA and 1 mM P4S. Because
THIP was a hydrochloride salt, high concentrations will affect the
driving force, resulting in an underestimation of the THIP-induced
currents. The values of the measured currents induced by 1, 3, and 10
mM THIP were thus increased by 0.6, 2.2, and 7.4%, respectively,
before analysis. All data values are means  SD.
Drugs and chemicals. All compounds were purchased from Sigma,
except diazepam (Roche) and THIP (Tocris Bioscience). GABA and P4S
were prepared as 1 M stock solutions in recording solution. THIP hydro-
chloride was first prepared at a 30 mM concentration in recording solu-
tion; pH was then readjusted to 7.4 with NaOH before serial dilutions
(Mortensen et al., 2010). Diazepam was prepared as a 10 mM stock solu-
tion in DMSO. Aliquots were stored at20°C.
Results
Effect of diazepam on GABA agonist potency and efficacy
Using 122S GABAARs expressed in Xenopus oocytes, we ex-
amined the potentiation by diazepam of responses to saturating
concentrations of the partial agonists THIP and P4S. Diazepam
(1 M) increased the maximal currents elicited by 10 mM THIP
and 1mM P4S by 22 8 and 76 18%, respectively (Fig. 1A). In
contrast, responses to saturating GABA (1 mM) were virtually
unaffected by diazepam (Fig. 1A). The increased maximum re-
sponse to 1 mM P4S was reproduced with a super-saturating 10
mMP4S, yielding a 61 12%potentiation by diazepam (Fig. 1A).
To investigate how diazepam affected GABA, THIP, and P4S
responses, agonist concentration–response curves were con-
B
R
el
at
iv
e 
C
ur
re
nt
 
1 10 100 103
0.0
0.2
0.4
0.6
0.8
1.0
 GABA
+ DZ
 P4S
+ DZ
[Agonist] (µM) 
104
 THIP
 + DZ
20 s
120 nA
1 mM P4S
1 µM DZ
A
P
ot
en
tia
tio
n 
by
 1
 µ
M
 d
ia
ze
pa
m
 
0.8
1.0
1.2
1.4
1.6
1.8
2.0
2.2
10
mM
 P
4S
1m
M 
P4
S
1m
M 
GA
BA
10
mM
 TH
IP
Figure1. DiazepamincreasesTHIPandP4Spotenciesandefficaciesat122Sreceptors.A, Left,Membranecurrentsactivatedby1mMP4S intheabsence,presence,andafter recovery frompotentiation
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5), and 10mM THIP (n	 4). Control current amplitudes	 1. B, Concentration–response curves for GABA (black), THIP (red), and P4S (blue) under control conditions (open symbols, solid lines) and in the
presenceof1Mdiazepam(filled symbols, dotted lines). Curvesweregenerated fromtheHill equation forGABA in control (Imaxnormalized to1; EC50	15322M;nH	0.840.02;n	5)and in1M
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in1Mdiazepam(Imax	0.870.03;EC50	31485M;nH	0.930.11;n	4);andforP4S incontrol (Imax	0.270.03;EC50	18530M;nH	0.860.02;n	5)and in1Mdiazepam
(Imax	 0.51 0.07; EC50	 63 13M;nH	 0.90 0.01;n	 4).
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structed in the absence and presence of 1Mdiazepam. Although
diazepam increased the potencies of GABA (approximately four-
fold) and THIP and P4S (approximately threefold), it only in-
creased themaximal current for THIP andP4S (Fig. 1B), which is
likely to reflect a change in the macroscopic efficacy of these
partial agonists. This was complemented by directly measuring
the ratio of maximal currents (IP4S/IGABA) elicited by saturating
(1mM) concentrations of P4S andGABA (control, 26 5%;with
diazepam, 43 7%; n	 6; data not shown).
BDZs and the preactivation step: a receptor model
Consistent with previous studies, these results clearly show
that a BDZ agonist does not modulate GABAAR function sim-
ply by increasing the binding of GABA agonists but instead
affects channel gating. However, other studies primarily dis-
counted this possibility on the basis that BDZs do not affect
the efficacy of GABA-induced single-channel openings (Rog-
ers et al., 1994). To reconcile these views, we investigated
whether BDZ modulation could be accounted for by a linear
three-step model incorporating agonist binding, preactiva-
tion, and channel activation (model 1; Fig. 2A).
In this model, we postulated that BDZ agonists can potentiate
GABAAR function by just increasing the preactivation conforma-
tional constant, F, by a constant factor, C (Fig. 2A). To provide
starting values for themodel parameters,weuseddirect substitution
with the following equations and values for the maximum open
probabilities (Po,max) and half-maximally effective concentrations
(EC50)obtained forGABA,THIP, andP4Sunder control conditions
and in the presence of a BDZ.
For the three-step linear model 1, the open probability (Po
Ctrl)
is given by the following:
P0
Ctrl 
A.E.F
K  A  1  F  E.F
(1)
where K is the agonist dissociation constant, F is the preacti-
vation conformation constant, [A] is the agonist concentra-
tion, and E is the efficacy of channel gating. Similarly, the open
probability in the presence of BDZ (Po
BDZ) is given by the
following:
Po
BDZ 
A.E.C.F
K  A  1  C.F  E.C.F
(2)
By rearranging Equation 1,
Po
Ctrl 
E.F
1  F  E.F
1 
K
A  1  F  E.F
the following features are evident: (1) slope coefficient, nH 	 1,
(2) maximal open probability is given by
Po,max
Ctrl 
E.F
1  F  E.F
(3)
and (3) the half-maximally effective concentration is
EC50
Ctrl 
K
1  F  E.F
(4)
Equivalent equations can be derived for Po,max
BDZ and EC50
BDZ, replac-
ing F by C.F.
Determining the ratio EC50/Po,max from Equations 3 and 4
yields the following equality:
EC50
Ctrl
Po,max
Ctrl 
K
E.F
(5)
which in the presence of a BDZ equates to
EC50
BDZ
Po,max
BDZ 
K
E.C.F
(6)
The ratio of Equations 5 and 6 provides a value for C obtained
from the agonist EC50 values and the relative maximal current
responses:
C 
EC50
Ctrl
EC50
BDZ 
Po,max
BDZ
Po,max
Ctrl 
EC50
Ctrl
EC50
BDZ 
EffBDZ
EffCtrl
(7)
where Eff is the macroscopic efficacy of the agonist. Thus, deter-
mining C does not require knowledge of the absolute maximal
open probabilities. Rearranging Equation 3 yields
1
Po,max
Ctrl  1 
1  F
E.F
(8)
K F E C
GABA
P4S
30 mM
220 µM 0.22
31 5.7
1.55
4
4
B
THIP 5 mM 41 3.5
 GABA
+ DZ
 P4S
O
pe
n 
pr
ob
ab
ili
ty
[Agonist] (µM) 
0.0
0.2
0.4
0.6
0.8
1.0
1 10 100 103 104
+ DZ
 THIP
+ DZ
A + R AR AF AR*
binding preactivation opening
K F E
Control:
A + R AR AF AR*
K C.F E
In diazepam:
A Model 1
Figure 2. Linear receptor model of diazepam modulation at GABAARs. A, Top, three-
step model describing the activation of GABAARs (R) by GABA agonists (A), incorporating
an agonist dissociation constant (K), a preactivation constant (F), and an efficacy constant
for channel opening (E). AR represents the resting agonist-bound state, AF the preactiva-
tion state, and AR* the activated open channel state. Bottom, In the same model, diaze-
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 1). B,
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mental data points are replotted from Figure 1 B to assess the adequacy of themodel. Data
are normalized to a GABA Po,max of 0.85 (see Results). These concentration–response
curves predict Po,max and EC50: GABA control, 0.847 and 144M and with diazepam, 0.850
and 36.1M; THIP control, 0.636 and 909M and with diazepam, 0.737 and 263M; and
P4S control, 0.218 and 141M and with diazepam, 0.420 and 68M. The values used to
generate the model curves are tabulated.
Gielen et al. • Benzodiazepines and Preactivation of GABAA Receptors J. Neurosci., April 25, 2012 • 32(17):5707–5715 • 5709
with an equivalent expression in the presence of a BDZ:
C. 1Po,maxBDZ  1  1  C.FE.F (9)
Subtracting Equation 8 from Equation 9 yields
C. 1Po,maxBDZ  1   1Po,maxCtrl  1  C  1E
Rearranging in terms of E,
E 
C  1
C. 1Po,maxBDZ  1   1Po,maxCtrl  1
(10)
According to Equation 4 and its equivalent in the presence of BDZs,
K EC50
Crtl 1 F E.F) EC50
BDZ 1 C.F E.C.F)
Thus,
EC50
Ctrl EC50
BDZ F.[C.EC50
BDZ.1 E) EC50
Ctrl1 E)]
Using Equation 7, this equates to
1  EC50BDZEC50Ctrl   F.1  E.Po,max
BDZ
Po,max
Ctrl  1
Providing an estimate of F,
F 
1 
EC50
BDZ
EC50
Ctrl
1  E.Po,maxBDZPo,maxCtrl  1
(11)
After calculating E and F, Equations 4 and 5 provide a value for K.
According to Equation 11, although we require Po,max
Ctrl  Po,max
BDZ to
provide accurate values forF andK, it shouldbenoted that this is not
needed for the determination of E, C, and the ratio K/F. Moreover,
when Po,max
Ctrl  Po,max
BDZ , our model predicts high values of F andK.
To numerically determine the model parameters, we first esti-
mated the values of EC50
Ctrl and EC50
BDZ (in the presence of diaze-
pam) and Po,max
Ctrl and Po,max
BDZ for GABA, THIP, and P4S. A good
estimate of C can then be obtained by assuming the maximal re-
sponses to GABA are unchanged by diazepam, because the calcula-
tion of C only requires the macroscopic efficacy of the agonist (see
Eq. 7). We then set Po,max
Ctrl (GABA) to 0.85, which is consistent with
previous single-channel recording estimates (Mortensen et al., 2004;
Lema and Auerbach, 2006; Keramidas and Harrison, 2010). This
allowed E to be approximated as Po,max for GABA is thought to be
unchangedbydiazepam,which concurswithprevious studies (Rog-
ers et al., 1994).However,F andK cannot be determined in thisway,
because our model strictly requires that diazepam does in-
crease Po,max (GABA) (see Eq. 11). Considering that a significant
change in Po,max (GABA) should have been experimentally ob-
served, we arbitrarily postulated that the diazepam-induced
change in Po,max (GABA) is 3%.
We then considered two scenarios in which
Po,maxBDZ GABAPo,maxCtrl GABA  1
is either 0.3% (scenario 1) or 3% (scenario 2). The value for
Po,max
Ctrl (THIP) was determined according to the ratio of maximal
currents evoked by 10 mM THIP and 1 mM GABA in control,
whereas the value for Po,max
BDZ (THIP) was inferred from the potentia-
tion of THIP-induced currents by diazepam. The values for Po,max
Ctrl
(P4S) and Po,max
BDZ (P4S) were determined according to the ratio of
maximal currents evoked by 1mM P4S and 1mMGABA, and nota-
bly, Po,maxBDZ P4SPo,maxCtrl P4S  1 did not vary significantly regardless of the
scenario. Thus, for P4S, all parameters were unaltered by the two
scenarios (CP4S	 5.64 and 5.82, EP4S	 1.23 and 1.34, FP4S	 0.32
and 0.29, andKP4S	 317 and 309M for scenarios 1 and 2, respec-
tively). For GABA, both C and E were also essentially unaffected
(CGABA	 4.39 and 4.53, EGABA	 5.84 and 8.00, for scenarios 1 and
2, respectively); however, bothFGABA andKGABA varied significantly
(FGABA	 31.9 and 2.43; KGABA	 33.6 and 3.5 mM for scenarios 1
and 2, respectively), whereas the ratioK/F remained relatively unal-
tered.Ourmodel therefore suggests thatKGABA cannot be accurately
determined in this way and that its value could lie anywhere above
3.5mM, whereas the lower limit of FGABA is2.4. By comparing the
parameter values obtained for GABA, THIP, and P4S, it is notable
that C is similar for all three agonists (Table 1). Considering the
likelihood that small changes toC could just reflect variability in the
fitting of the experimental data, we fixedC to an intermediate value
of 4 and used themodel to generate curve fits whereupon diazepam
induced an increase in Po,max
Ctrl (GABA) of0.3%, providing an accu-
rate fit to the data (Fig. 2B).
Alternative models: agonist binding and channel gating
Although the potentiation of agonist activation of GABAARs
by BDZs seemed adequately explained by changes to the pre-
activation step, we next considered alternative models in
which diazepam would either increase the efficacy of channel
opening by a factor CE (model 2; Fig. 3A) or decrease the
agonist dissociation constant by a factor CK (model 3; Fig. 3B).
Formodel 2, because Equation 7 is still valid, we decided to use
the same value for CE as that used for C in model 1 (CE	 4). The
ratio of EC50 values gives
EC50
Ctrl
EC50
BDZ 
1  F  E.CE.F
1  F  E.F
 1  CE  1.
E.F
1  F  E.F
This equates to
EC50
Ctrl
EC50
BDZ  1  CE  1.Po,max
Ctrl
Rearranging for EC50
BDZ,
EC50
BDZ 
EC50
Ctrl
1  CE  1.Po,max
Ctrl (12)
Table 1. Parameters for the three-stepmodel
Po,max
Ctrl Po,max
BDZ EC50
Ctrl EC50
BDZ C E F K (mM)
2S
GABA 0.850 0.853 153 35 4.4 5.84 31.9 33.6
P4S 0.230 0.441 140.4 54.1 5.6 1.23 0.32 0.32
THIP 0.655 0.735 834 314 3.0 3.61 1.11 5.09
2L
GABA 0.850 0.853 53.9 13.6 4.0 5.85 30.9 11.5
P4S 0.075 0.185 138.8 64.2 5.3 0.388 0.264 0.190
Parameters for the three-step model in the scenario in which diazepam increases Po,max (GABA) by0.3% (see
Results).
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Moreover,
Po,max
BDZ
Po,max
Ctrl  CE.
EC50
BDZ
EC50
Ctrl
Thus,
Po,max
BDZ 
CE.Po,max
Ctrl
1  CE  1.Po,max
Ctrl (13)
Equations 12 and 13 show that the prediction made by model 2
does not depend on the exact values of E, F, and K, because the
diazepam-induced increase in agonist potency and open proba-
bility are expressed as a function of CE and the potency and open
probability in control.
Similarly to our first model, model 2 predicts a potentia-
tion of responses elicited by saturating agonist concentrations.
However, the predicted potentiations considerably overesti-
mate the experimental values (Fig. 3A). For instance, model 2
predicts a 13% increase in Po,max (GABA) and a 142% increase
in Po,max (P4S), which do not accord with our experiments.
In the final alternative model (model 3), the ratio of the EC50
values in the absence and presence of a BDZ gives
EC50
Ctrl
EC50
BDZ  CK
To model our data with the same value of CK regardless of the
agonist, we used the mean value (3.3) obtained from the individ-
ual determinations of CK for GABA, THIP, and P4S.
Although this model, as expected, accounted for the diazepam-
induced lateral shift of the agonist concentration–response
curves to higher potency, it failed to account for the potentiation
of responses to saturating concentrations of partial agonists (Fig.
3B). Together, our first model, in which diazepam affects just the
preactivation step, is the only one able to reproduce the experi-
mental results.
The preactivation step model applies to 2L
subunit-containing GABAARs
The 2S subunit has been reported recently to produce anoma-
lous results because of unusual interactions with other GABA
receptor subunits (Boileau et al., 2010). To ensure that our results
were unaffected by this potential anomaly, we expressed
122L GABAARs and constructed GABA and P4S concentra-
tion–response curves in the absence and presence of 1 M diaze-
pam. In control, the GABA concentration–response curve
indicated a higher apparent affinity and Hill coefficient (EC50	
53.9  8.5 M; nH 	 1.16  0.10; n 	 8) compared with that
obtained with 2S-containing receptors. The macroscopic effi-
cacy of P4S was also lowered (Fig. 4A), possibly indicative of 2S
engaging in anomalous subunit interactions. Nevertheless, diaz-
epam (1 M) had similar effects on 122L GABAARs com-
pared with 2S-containing receptors. Diazepam increased the
potencies of bothGABA (4-fold; EC50	 13.6 2.1Mand nH	
1.18 0.14 in diazepam; n	 5) and P4S (2.2-fold; in control and
diazepam, respectively, EC50	 139 27 and 64.2 1.3M; nH	
0.92 0.06 and 1.02 0.01; n	 6 and 5) and increased the relative
efficacy of P4S (2.5-fold) without affecting the current induced by
1mMGABA (potentiation by 6 3%; n	 9).
After normalizing Po,max
Ctrl (GABA) to 0.85 and hypothesizing
that diazepam potentiates the maximal GABA current by an un-
detectable value of 0.3% as proposed for 2S-containing recep-
tors (see above), we refitted our data with the three-step model 1
in which diazepam increases the preactivation constant (F) by
4.6-fold, determined as the mean of the values obtained for
GABA and P4S (Table 1). Despite changing the 2 subunit, the
model still provides an accurate fit of the experimental data (Fig.
4A,C). Notably, the alternative model 2, in which diazepam in-
creases the efficacy of gating (E), failed to fit the data and over-
estimated the macroscopic efficacies for both GABA and P4S in
the presence of diazepam (Fig. 4B,C). For model 1, proposing
that BDZs modulated the preactivation state, the increase in F
predicts a diazepam-induced 2.5-fold potentiation of responses
to 1 mM P4S, which is consistent with the experimental value
(2.75 0.18; n	 9). In contrast, frommodel 2, the increase in E
predicts a much stronger potentiation of 3.7-fold (Fig. 4C).
Model 3, in which diazepam decreases the agonist dissociation
constant was discounted because it cannot account for the in-
creased macroscopic efficacy of P4S in the presence of diazepam.
Therefore, as for 2S-containing receptors, the results obtained
with 122L GABAARs are entirely in accord with diazepam
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Figure 3. Alternative models fail to describe diazepammodulation at122S recep-
tors. A, Top, Model 2 in which diazepam causes an increase in the efficacy of channel
opening (CE 
 1). Bottom, Concentration–response curves predicted by model 2 with
CE	 4 and with the same values for K, F, and E as for model 1 in Figure 2. These concen-
tration–response curves predict Po,max and EC50 in diazepam: GABA, 0.957 and 40.6 M;
THIP, 0.875 and 313M; and P4S, 0.528 and 85.1M. AR represents the resting agonist-
bound state, AF the preactivation state, and AR* the activated open channel state. B, Top,
Model 3 in which diazepam causes a reduction in the agonist dissociation constant (CK

1). Bottom, Concentration–response curves predicted by model 3 with CK	 3.3 and with
the same values for K, F, and E as in Figure 2. These concentration–response curves predict
EC50 in diazepam: 43.6M for GABA; 275M for THIP; and 42.7M for P4S.
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modulating the preactivation step in the GABAAR activation
pathway.
Preactivation step and the agonist binding sites
The outcome of the fitting procedure for the experimental data
using ourmodel is independent ofwhetherwe incorporate one or
two agonist binding steps. However, given that GABAARs require
the binding of two agonist molecules for efficient gating (Miller
and Smart, 2010), it is conceivable that the modulation by BDZ
ligands might differentially affect one or other of the agonist
binding sites. The increase in the preactivation constants by
BDZs may therefore reflect a local conformational rearrange-
ment at a specific neurotransmitter binding site or a global rear-
rangement equally affecting both binding sites.
A local effect would be plausible given the nonsymmetrical
location of the two GABA binding sites relative to the BDZ bind-
ing site (Fig. 3B). A conformational rearrangement at just one
GABA binding site should be resolved by selective mutation.
However, limiting the disruption to a single specified GABA
binding site is difficult when expressing 122S heteromeric
receptors using separate cDNAs. Previously, concatamers have
been combined to constrain receptor subunit position and stoi-
chiometry for GABAARs (Minier and Sigel, 2004; Baur et al.,
2010; Bracamontes et al., 2011).
In a recent study to decipher the importance of each individ-
ual agonist binding site to the modulation by diazepam, a 2–2
dimer and1–2–1 trimer, incorporating singleGABAbinding
site mutations, were coinjected into Xenopus oocytes (Baur and
Sigel, 2005). Using the2Y205Smutation, which strongly disrupts
GABA binding (Amin and Weiss, 1993), submaximal GABA re-
sponses were potentiated when either the dimer or trimer con-
struct contained the binding site mutation. This suggests that
BZDs affect the channel opening of GABAARs activated from
either agonist binding site. However, the use of dimers and trim-
ers can give rise to expression artifacts (Ericksen and Boileau,
2007; Sigel et al., 2009). This potential uncertainty in terms of
GABAAR expression and stoichiometry is essentially removed by
using pentameric concatamers (Baur et al., 2006).
To overcome those possible limitations, we generated a pen-
tameric concatamer with a defined stoichiometry and arrange-
ment of receptor subunits (Fig. 5B). This concatamer is a single
protein with the C terminus of each subunit connected to the N
terminus of the following subunit via a small inert linker (Fig.
5B). The 2Y205S mutation is so disruptive that it prevents a pre-
cise measure of GABA potency. The GABA concentration–re-
sponse data for mutant concatamers containing 2Y205S in the
second 2 subunit required fitting with a two-binding site equa-
tion with high affinity (570 M; relative amplitude,5%; n	 3)
and dominant low-affinity components (160mM; relative ampli-
tude,95%; n	 3), the latter presumably corresponding to the
potency at the mutated binding site (data not shown). We
therefore decided to mutate tyrosine 157 in the 2 subunit to
serine (Y157S), an exchange that greatly disrupts GABA bind-
ing (Amin and Weiss, 1993) but still enables a reliable mea-
surement of GABA potency. This allows a comparison of the
diazepammodulation of various GABAARs when GABA occu-
pancies are similar.
GABA concentration–response curves were constructed for
wild-type andmutant concatamers containing2Y157S in the first
(SU1–Y157S) or second (SU3–Y157S; Fig. 5B)2 subunit. GABA
retained a similar potency at the wild-type concatamers to that
measured for wild-type 122S heteromers (EC50	 120 M).
However, GABA potency was reduced by 100-fold for the SU1–
Y157S and SU3–Y157S concatamers (EC50	 22.6 and 10.4 mM,
respectively; Fig. 5A).When the2 subunitmutations were com-
bined in SU1–Y157S/SU3–Y157S concatamers, GABA potency
was further reduced (EC5075mM, n	 4; data not shown). The
non-additive nature of the two 2 subunit mutations suggests
that, at singly mutated concatamers, the agonist potency corre-
sponds mainly to that of GABA binding to the mutated site.
The potentiating effect of diazepam on GABA-activated cur-
rents was then examined using the wild-type and two single
mutant concatamers. For each concatamer, 1 M diazepam po-
tentiated currents induced by GABA (EC15) to similar extents
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Figure 4. Diazepammodulation of122L receptors is best described by changes to the
preactivation constant, F. A, Model 1-generated concentration–response curves for GABA
(black) and P4S (blue) in the absence (solid lines) and presence (dotted lines) of diazepam.
Diazepam is presumed to increase the preactivation constant by 4.6-fold. The experimental
data points were normalized, after fitting by the Hill equation, to give a GABA Po,max of 0.85.
These concentration–response curves predictPo,max and EC50: GABA control, 0.853 and61.6M
and with diazepam, 0.856 and 13.4M; P4S control, 0.077 and 139M and with diazepam,
0.180 and 70.4M. The values used to generate themodel curves are tabulated.B, Alternative
model 2, in which diazepam induces a 4.6-fold increase in the efficacy of channel opening.
These agonist concentration–response curves predictPo,max and EC50 in diazepam:GABA, 0.964
and15.1M; P4S, 0.278 and109M.C,Magnified viewof thepredictions, fromA andB, for the
diazepam-induced modulation of P4S responses.
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(potentiation: wild type, 2.42  0.45-fold; SU1–Y157S, 2.26 
0.24; and SU3–Y157S, 2.29  0.24; Fig. 5B,C). Of note, at their
GABA EC15 (2–4 mM range), the two mutant concatamers
should have their wild-type GABA binding site almost saturated
with GABA. Together, these results suggest that BDZ agonists
cause a global conformational rearrangement of the GABAAR to
potentiate function rather than a local conformational change at
a specific GABA binding site.
Discussion
TheGABAAR is a widely recognizedmolecular target for BDZs to
exert their anxiolytic and anticonvulsant effects. Although BDZs
were considered to increase the binding affinity of the receptor
for GABA, recent evidence was not in favor of such an explana-
tion, suggesting an effect on receptor gating. Here, we provide a
plausible explanation that links the previous observations by
demonstrating that BDZs can increase the adoption of a transi-
tional receptor state, the preactivated state. This state of the re-
ceptor is likely to encompass several distinct brief transitional
states that are passed through after GABA
binding, before proceeding to channel
activation.
By using a simple receptor model, we
present a plausible mechanism that ac-
counts for the experimental observations.
Of particular importance is the result that
the BDZ-induced increase in the preacti-
vation constant is similar regardless of
whether the receptor is activated byGABA
or partial agonists. This suggests that the
putative BDZ-induced change in the pre-
activation constant is independent of the
nature of the agonist occupying theGABA
site, depending solely on the BDZ.
According to such a model, we can
make several assertions. (1) If the value of
(F  E.F) is already much more than 1,
the limiting step to setting Po,max is the
final step involving channel opening
Po,max	E/(1E), which implies that BDZ
agonists cannot significantly potentiate
maximal agonist-induced responses. This
situationpertains for the full agonistGABA.
(2) Even if (F E.F)
 1, an increase of the
preactivationconstantbyBDZagonists (i.e.,
C
 1) would increase the agonist potency
(often interpreted as affinity), indicative of
the many studies reporting the modulation
of GABA responses by BDZ agonists. (3)
Consistent with the actions of partial ago-
nists at glycine and nACh receptors (Lape et
al., 2008), the partial agonist nature ofTHIP
andP4S stemsmainly froma lowpreactiva-
tion constant. The diazepam-induced in-
crease in this constant can entirely account
for the increase in both THIP and P4S po-
tency and efficacy. (4)We can now propose
a unifying view of the mode of action of
BDZ agonists (e.g., diazepam) and inverse
agonists[e.g.,methyl-6,7-dimethoxy-4-ethyl-
-carboline-3-carboxylate (DMCM)]. In-
deed, DMCM reduces the efficacy of P4S
(Maksay et al., 2000), and DMCM is able
to inhibit spontaneously active GABAARs
(Campo-Soria et al., 2006). This indicates that this class of BDZ-
site ligands acts on the gating of the receptor and not on the
binding of GABA agonists. Our model therefore predicts that
modulation by inverse agonists could be explained by a decrease
in the preactivation constant (C 1). In addition, BDZ antago-
nists such as flumazenil, which compete with BDZ-site ligands
but do not modulate GABA-induced currents (Rudolph and
Knoflach, 2011), would, in the context of the model, produce no
change to the preactivation constant (i.e., C 	 1). Importantly,
when dwell time distributions are corrected for missed events,
changes to the preactivation constant should not produce any
alteration to the open time distribution of single-channel events
but should influence the shut time distribution. This again is
consistent with observations of GABA single channelsmodulated
by diazepam or DMCM (Rogers et al., 1994).
TheMonod–Wyman–Changeux (MWC)model has also been
used to account for the effects of BDZs on GABA-activated and
spontaneously open 122 GABAARs (Downing et al., 2005;
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Figure 5. Effect of diazepam on pentameric concatamers incorporating single GABA binding site mutations. A, GABA concen-
tration curves for wild-type (WT)2–1–2–1–2S concatamers (black circles; EC50	 120 15M; nH	 1.38 0.17;
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Ru¨sch and Forman, 2005; Campo-Soria et
al., 2006). In all thesemodels, however, no
preactivated state is depicted (Fig. 6A).
Diazepam was considered to increase the
gating efficacy. This could account for the
influence of saturating concentrations of
diazepam on the GABA concentration–
response curves (Downing et al., 2005;
Campo-Soria et al., 2006). However,
when studying the effect of high diazepam
concentrations in these models, the GABA
responses were normalized to give a maxi-
mal response of 1. Under such circum-
stances, diazepam, of course, cannot
potentiate the maximal GABA response. In
contrast, if the experimental data are nor-
malized to the maximum open probability,
which for GABAARs is 1, such a gating
model would predict that diazepam poten-
tiates the responses to saturating concentra-
tions of GABA. Similarly, such an allosteric
MWC model could account for the slight
leftward shift of the GABA concentration–
response curve induced by a low (10 nM)
concentration of the BDZ midazolam
(Ru¨sch andForman, 2005), but in this latter
study, the calculatedmaximum open prob-
ability is also expected to increase by 6.3%
by 10 nMmidazolam (from 0.862 to 0.916),
and saturating concentrations of midazo-
lam are expected to increase the maximal
open probability by 10.2% (from 0.862 to
0.95), quite similar towhatwe predict when
we use a model in which diazepam affects
the gating efficacy. Hence, these MWC
models cannot account for the effects of
BZDs at saturating concentrations ofGABA
agonists. We therefore expanded this allo-
steric model to incorporate a preactivation
step. In the resultingmodifiedMWCmodel
(Fig. 6B), diazepamishypothesized to affect
the equilibrium preactivation constant (L0)
between the preactivated (F) and resting
(R) statesbyapotency ratiod. In thismodel,
diazepamdoesnot affectL1, the equilibrium
gating constant between the preactivated
and the open (O) states. We also hypothe-
sized the binding of the agonist to affect L0,
rather than L1, by a potency ratio c. This is
indeedmore consistentwith thepartiality of
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Figure 6. Relationship of preactivation model to the MWCmodel. A, MWC model used by Ru¨sch and Forman (2005), which is
similar to the models used by Downing et al. (2005) and Campo-Soria et al. (2006). R and O depict the resting and open states,
respectively. The models in schemes A–C all use the same nomenclature in which K represents ligand dissociation constants for
either BDZs (Bz; KBz) or the agonist, e.g., GABA (G; KG). Note the use of statistical factors (e.g., 2KG and KG/2) attributable to the
4
provision of two agonist binding sites in these models. Bz and
G affect L0 , the equilibrium gating constant between resting
(R) and open (O) states of the receptor, by the potency ratios d
and c, respectively. Note L0	 [R]/[O]. B, The MWC model is
expanded to incorporate a preactivated state, F. In thismodel,
Bz and G affect L0, the equilibrium gating constant between R
and F, and not L1, the equilibrium gating constant between
states F and O (L1	 [F]/[O]). C, Highlighted pathways (black)
are shown corresponding to the three-step model 1 used to
describe the effect of diazepam in the current study (see Fig.
2A). Of note, 1/d corresponds to the constant C in model 1.
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agonists stemmingmainly fromdifferences in the preactivation step
(Lape et al., 2008). The three-step preactivation model used in the
present study corresponds to a subset of thismodifiedMWCmodel,
inwhichwe consider there is no spontaneous activity of the receptor
(i.e., L0

 1

 c) and inwhichwe consider only one single agonist
binding site (Fig. 6C). In this analogy, it is worth noting that the
reciprocal of the potency ratio d, in theMWCmodels, corresponds
to the constantC fromour three-stepmodel.Our results, suggesting
C 	 4, are thus consistent with published values for d (0.3;
Downing et al., 2005; Ru¨sch and Forman, 2005).
Onepotentially confounding issue not yet considered concerns a
contribution fromfastdesensitization. It is conceivable that themac-
roscopic effects ofBDZs,measuredwithwhole-cell responses,might
be subject to a dual increase in macroscopic efficacy and desensiti-
zation. In such a scheme, the maximal BDZ-induced potentiation
would be reduced through desensitization, possibly accounting for
our data. However, this is not in accord with the effect of BDZs on
singleGABAchannel currents, because diazepamalteredneither the
meanopen channel duration (for 3MGABA)nor the shortest shut
time constants (Rogers et al., 1994). On the contrary, diazepam
shortened the longest shut time constants and increased the fre-
quency of bursts, both effects that are consistent with diazepam fa-
cilitating apreactivation step rather thanpromotingboth gating and
desensitization (Rogers et al., 1994; Lape et al., 2008).
A recent studyonnAChreceptorshas reported the existenceof at
least two intermediate preactivation states (called “primed states”)
that are transitionalbetweenrestingandopenstates (Mukhtasimova
et al., 2009). At the ACh binding site, primingwas thought to corre-
spond to the transition of the agonist binding loop C from an un-
capped to capped conformation. The loop C capping during
receptor priming is probably accompanied by a global conforma-
tional change in the extracellular domains, as proposed after struc-
tural analyses of “open” and “shut” states of the bacterial homologs
of Cys-loop receptors (Hilf and Dutzler, 2008; Bocquet et al., 2009;
Miller and Smart, 2010). Such a global conformational rearrange-
ment would be consistent with our explanation of the effects of
BDZs on GABAARs deduced using the concatamers. It is indeed
plausible that BDZs promote, in addition to a C-loop capping, the
rotation of the extracellular domains of subunits participating in the
interfacialBDZsite.This rotationcould in turnbe communicated to
the neighboring subunits reaching both GABA binding sites. If we
hypothesize that preactivation involves conformational changes in
the extracellular domain, it is plausible that ligands that bind to this
domain act primarily through a change in the preactivation step, as
suggested in our extendedMWCmodel.
Together, our study demonstrates that the BDZs can alloster-
ically modulate GABAARs by modifying the preactivation step,
without affectingGABAbinding or channel gating. The discovery
that an allosteric modulator can act in this way at a Cys-loop
receptor may facilitate our understanding of the molecular
mechanisms underlying the elusive preactivation process.
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